COMMUNIQUÉS West-GlobeNewswire

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
22/06/2026
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47 phox -deficient [...]
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
22/06/2026
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD [...]
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
22/06/2026
TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products [...]
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
22/06/2026
DALLAS, June 22, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today announced that it has partnered [...]
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
22/06/2026
Platform Expected to Target Expansion into Multi-Billion-Dollar Cardiovascular Market with Potential Class II Diagnostic Regulatory Path Architecture Supports Future Expansion into Denervation, including Renal, [...]
GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage
22/06/2026
AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " [...]
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
22/06/2026
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today [...]
Novel Key Terms For Managing CIDP Published in Neurology® Journal
22/06/2026
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- The GBS|CIDP Foundation International is thrilled to announce the publication of shared key terms to describe the management of Chronic Inflammatory Demyelinating [...]
Route 92 Medical Announces First Commercial Cases in Canada
22/06/2026
Procedures follow Health Canada Medical Device License for the Company’s advanced neurovascular portfolio More than 100,000 patients suffer from strokes annually in Canada WEST JORDAN, Utah, June 22, 2026 (GLOBE [...]
LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
22/06/2026
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July [...]
Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis
22/06/2026
Enrollment expected to complete Q1 2027; topline results anticipated 1H 2028; BLA filing targeted for 2H 2028 Phase 1/2 data demonstrated ATSN-201's ability to reverse structural damage to the retina and improve vision [...]
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
22/06/2026
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for [...]
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
22/06/2026
Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
22/06/2026
LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing- [...]
NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization
22/06/2026
Strong Capitalization Foundation Supports Strategic Growth and Market Stability BANGKOK, June 22, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”) today announced that NewGen’s [...]
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million [...]
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
22/06/2026
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug [...]
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
22/06/2026
Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“ [...]
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which [...]

Pages